CANIGEN DHPPi/L

Main information

Documents

Localization

  • Available in:
  • Canigen DHPPi/L
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • live canine distemper virus + live canine adenovirus + live canine parainfluenza virus + live canine parvovirus + inactivated le
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0237/001
  • Authorization date:
  • 16-12-2011
  • EU code:
  • FR/V/0237/001
  • Last update:
  • 09-08-2016

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

CANIGEN/CANIXINDHPPi/L –FR/V/0/0237/001/MR

Thereleaserequirementsforthefinishedproductarethefollowing:

Freeze-driedfraction

test Acceptabilitylimits

aspect Whitepellet

pH 7.2+/-0.5

Solubility Satisfactory

Titres –inlog

10 TCID

CDV

CAV-2

CPiV

CPV

≥4.1

≥5.1

≥5.9

≥5.3

Sterility

mycoplasma

extraneousagents Sterile

Absence

absence

Residualhumidity 0.1-3%

Liquidfraction

test Acceptabilitylimits

Aspect Translucidliquid

pH 7.2+/-0.5

Volume 1.2+/-0.2

Mercurothiolatecontent <6.35µg/ml

potency ConformtoEPtestdescribedin

monograph0447

Sterility Sterile

Inactivation Absenceofleptopsirae

25-10-2018

Canigen L4 (Intervet International B.V.)

Canigen L4 (Intervet International B.V.)

Canigen L4 (Active substance: Leptospira interrogans serogroup Canicola serovar Portland-vere/Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni/Leptospira interrogans serogroup Australis serovar Bratislava/Leptospira kirschneri serogroup Grippotyphosa serovar Dadas) - Centralised - Yearly update - Commission Decision (2018)7138 of Thu, 25 Oct 2018

Europe -DG Health and Food Safety